Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy (Q44308117)

1 December 2017

title

Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy (English)

1 reference

1 December 2017

1 reference

1 reference

1 December 2017

Elinor Ben-Menachem

1 reference

1 December 2017

Pascal Edrich

series ordinal

1 reference

1 December 2017

Betty Van Vleymen

series ordinal

1 reference

1 December 2017

Bernd Schmidt

series ordinal

1 reference

1 December 2017

publication date

1 February 2003

1 reference

1 December 2017

1 reference

1 December 2017

1 reference

1 December 2017

issue

1-2

1 reference

1 December 2017

page(s)

57-64

1 reference

Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience.

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900247-4

7 January 2021

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900247-4

7 January 2021

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900247-4

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900247-4

7 January 2021

Long-term continuation of levetiracetam in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900247-4

7 January 2021

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900247-4

7 January 2021

Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900247-4

7 January 2021

Difficulties in extrapolating from clinical trial data to clinical practice: The case of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-1211%2802%2900247-4

7 January 2021

10.1016/S0920-1211(02)00247-4

Identifiers

DOI

1 reference

1 December 2017

1 reference